Redmond, WA - Cadence Neuroscience Inc., a cutting-edge medical company focused on revolutionizing the treatment of epilepsy through a unique neuromodulation approach, is pleased to announce the successful completion of its Series B funding round, raising $26 million. The round was led by prominent investors, including Mayo Clinic, F-Prime Capital, JAZZ Venture Partners, and Angelini Ventures.

Cadence Neuroscience aims to transform the field of neuromodulation by developing a groundbreaking system that can detect specific signals from the brain and deliver precise electrical stimulation to modify the activity of neural circuits. The company's pioneering technology, based on groundbreaking research performed at Mayo Clinic, offers a personalized approach with unprecedented potential to treat a wide range of neurological diseases that currently lack adequate treatment options.

The $26 million raised in this funding round will enable Cadence Neuroscience to further advance the development and commercialization of its innovative epilepsy treatment technology. The company's solution has already demonstrated remarkable breakthrough results and is currently undergoing evaluation in clinical trials. Cadence Neuroscience aspires to alleviate the suffering of millions of individuals worldwide, starting with those living with epilepsy.

"We are thrilled to have secured $26 million in Series B funding, which will be instrumental in accelerating our mission to revolutionize the treatment of epilepsy," said Kent Leyde, Founder of Cadence Neuroscience Inc. "This significant investment reflects the confidence and support of our esteemed investors and demonstrates the immense potential of our neuromodulation approach. We are grateful for their partnership and look forward to advancing our technology to positively impact the lives of patients."